Dr. Daniele on Impact of Regorafenib in HCC

Bruno Daniele, MD
Published: Friday, Jul 08, 2016


Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Regorafenib will change the treatment landscape because it significantly increases survival in patients, Daniele explains.

However, it is important to note the therapeutic sequence of systemic therapy because, overall, the combination of sorafenib (Nexavar) and regorafenib in sequence is associated with a median overall survival of 26 months.
 

<<< View more from the 2016 World Congress on GI Cancer


Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Regorafenib will change the treatment landscape because it significantly increases survival in patients, Daniele explains.

However, it is important to note the therapeutic sequence of systemic therapy because, overall, the combination of sorafenib (Nexavar) and regorafenib in sequence is associated with a median overall survival of 26 months.
 

<<< View more from the 2016 World Congress on GI Cancer


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x